DIVISLABNSEDivi's Laboratories Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 7 Nov, 2025 · 12:06 IST

Q2 FY26 PAT rises 35 percent to Rs 689 crore

Pat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.9%Reaction day
₹6875.00
prior close
₹6788.00
announcement price
In-mkt
timing
Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.0%-3.9% vs market
Pharmaceuticals peers, median of 156sector-0.0%-3.9% vs sector

On the reaction day the stock moved 3.9 pts less than Nifty 100 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.2
10m
-0.8
15m
-0.9
30m
-1.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-3.9-0.0-3.9-0.0-3.9
Next day
-2.5+0.3-2.7-0.7-1.8
2d
-5.0+0.7-5.8-0.9-4.2
3d
-5.2+1.3-6.5+0.1-5.3
4d
-4.0+1.3-5.3+0.2-4.2
5d
-5.2+1.4-6.6+0.0-5.2
1w
-5.9+1.4-7.3-0.3-5.6
15d
-6.0+2.2-8.2-1.6-4.4
1m
-8.0+1.0-9.0-5.3-2.7
2m
-3.3+2.4-5.7-2.8-0.6
3m
-10.7+1.3-12.0-7.3-3.4
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Divi's Laboratories reported unaudited consolidated Q2 FY26 revenue from operations of Rs 2,715 crore and total income of Rs 2,860 crore. PAT rose 35 percent year on year to Rs 689 crore, and PBT rose to Rs 912 crore. H1 FY26 PAT was Rs 1,234 crore, up 31 percent. Operating cash inflow reached Rs 1,645 crore. Forex gain was Rs 63 crore versus Rs 29 crore a year earlier, and the auditor's limited review was unmodified.

Likely market impact

Strong profit growth and cash generation help shareholders, but higher forex gains may not repeat and could make earnings volatile.